Literature DB >> 24631025

Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis.

Hong Xia1, Vidya Bodempudi1, Alexey Benyumov1, Polla Hergert1, Damien Tank1, Jeremy Herrera1, Jeff Braziunas2, Ola Larsson3, Matthew Parker1, Daniel Rossi1, Karen Smith1, Mark Peterson1, Andrew Limper4, Jose Jessurun5, John Connett6, David Ingbar1, Sem Phan7, Peter B Bitterman1, Craig A Henke8.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease of the middle aged and elderly with a prevalence of one million persons worldwide. The fibrosis spreads from affected alveoli into contiguous alveoli, creating a reticular network that leads to death by asphyxiation. Lung fibroblasts from patients with IPF have phenotypic hallmarks, distinguishing them from their normal counterparts: pathologically activated Akt signaling axis, increased collagen and α-smooth muscle actin expression, distinct gene expression profile, and ability to form fibrotic lesions in model organisms. Despite the centrality of these fibroblasts in disease pathogenesis, their origin remains uncertain. Here, we report the identification of cells in the lungs of patients with IPF with the properties of mesenchymal progenitors. In contrast to progenitors isolated from nonfibrotic lungs, IPF mesenchymal progenitor cells produce daughter cells manifesting the full spectrum of IPF hallmarks, including the ability to form fibrotic lesions in zebrafish embryos and mouse lungs, and a transcriptional profile reflecting these properties. Morphological analysis of IPF lung tissue revealed that mesenchymal progenitor cells and cells with the characteristics of their progeny comprised the fibrotic reticulum. These data establish that the lungs of patients with IPF contain pathological mesenchymal progenitor cells that are cells of origin for fibrosis-mediating fibroblasts. These fibrogenic mesenchymal progenitors and their progeny represent an unexplored target for novel therapies to interdict fibrosis.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24631025      PMCID: PMC4005984          DOI: 10.1016/j.ajpath.2014.01.012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  66 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

Review 2.  Pluripotent stem cells--model of embryonic development, tool for gene targeting, and basis of cell therapy.

Authors:  Katja Prelle; Nicola Zink; Eckhard Wolf
Journal:  Anat Histol Embryol       Date:  2002-06       Impact factor: 1.114

3.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

4.  Developmental potentials of hematopoietic and neural stem cells following injection into pre-implantation blastocysts.

Authors:  F Harder; N Kirchhof; S Petrovic; C Schmittwolf; M Dürr; A M Müller
Journal:  Ann Hematol       Date:  2002       Impact factor: 3.673

5.  Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction.

Authors:  Adam Giangreco; Susan D Reynolds; Barry R Stripp
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

6.  Bone marrow-derived progenitor cells in pulmonary fibrosis.

Authors:  Naozumi Hashimoto; Hong Jin; Tianju Liu; Stephen W Chensue; Sem H Phan
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

7.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

8.  A random variance model for detection of differential gene expression in small microarray experiments.

Authors:  George W Wright; Richard M Simon
Journal:  Bioinformatics       Date:  2003-12-12       Impact factor: 6.937

9.  Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.

Authors:  Luis A Ortiz; Frederica Gambelli; Christine McBride; Dina Gaupp; Melody Baddoo; Naftali Kaminski; Donald G Phinney
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

10.  Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Authors:  Hong Xia; Deanna Diebold; Richard Nho; David Perlman; Jill Kleidon; Judy Kahm; Svetlana Avdulov; Mark Peterson; John Nerva; Peter Bitterman; Craig Henke
Journal:  J Exp Med       Date:  2008-06-09       Impact factor: 14.307

View more
  35 in total

Review 1.  Rebuilding the injured lung.

Authors:  Peter B Bitterman
Journal:  Ann Am Thorac Soc       Date:  2015-03

2.  Hsp90 regulation of fibroblast activation in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Yunguan Wang; Rajesh K Kasam; Debora Sinner; Geereddy B Reddy; Anjaparavanda P Naren; Francis X McCormack; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2017-02-23

3.  Taking It Off: New Insights into the Role of Tyrosine Phosphorylation-dependent Pathways in the Pathogenesis of Pulmonary Fibrosis.

Authors:  Gregory P Downey; Yael Aschner
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

4.  Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease.

Authors:  Vishwaraj Sontake; Rajesh K Kasam; Debora Sinner; Thomas R Korfhagen; Geereddy B Reddy; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2018-08-23

5.  Transforming growth factor β1 alters the 3'-UTR of mRNA to promote lung fibrosis.

Authors:  Junsuk Ko; Tingting Mills; Jingjing Huang; Ning-Yuan Chen; Tinne C J Mertens; Scott D Collum; Garam Lee; Yu Xiang; Leng Han; Yang Zhou; Chun Geun Lee; Jack A Elias; Soma S K Jyothula; Keshava Rajagopal; Harry Karmouty-Quintana; Michael R Blackburn
Journal:  J Biol Chem       Date:  2019-09-05       Impact factor: 5.157

Review 6.  TGFβ as a therapeutic target in cystic fibrosis.

Authors:  Elizabeth L Kramer; John P Clancy
Journal:  Expert Opin Ther Targets       Date:  2017-12-13       Impact factor: 6.902

Review 7.  Extracellular matrix as a driver of progressive fibrosis.

Authors:  Jeremy Herrera; Craig A Henke; Peter B Bitterman
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

8.  Calcium-binding protein S100A4 confers mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis.

Authors:  Hong Xia; Adam Gilbertsen; Jeremy Herrera; Emilian Racila; Karen Smith; Mark Peterson; Timothy Griffin; Alexey Benyumov; Libang Yang; Peter B Bitterman; Craig A Henke
Journal:  J Clin Invest       Date:  2017-05-22       Impact factor: 14.808

9.  MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation.

Authors:  Chaoqun Huang; Xiao Xiao; Ye Yang; Amorite Mishra; Yurong Liang; Xiangming Zeng; Xiaoyun Yang; Dao Xu; Michael R Blackburn; Craig A Henke; Lin Liu
Journal:  J Biol Chem       Date:  2017-07-18       Impact factor: 5.157

10.  Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

Authors:  David M Habiel; Milena S Espindola; Ana L Coelho; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2018-02-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.